

### Acknowledgments

We thank J.J. Mekalanos for useful comments on this manuscript and Motiur Rahman for help with the nucleotide sequencing. We also thank the International Vaccine Institute funded by the Bill and Melinda Gates Foundation (Diseases of the Most Impoverished Program).

The ICDDR,B is supported by the aid agencies of the governments of Australia, Bangladesh, Belgium, Canada, Japan, Kingdom of Saudi Arabia, the Netherlands, Sweden, Sri Lanka, Switzerland, and the United States.

**M. Ansaruzzaman,\* N.A. Bhuiyan,\*  
G. Balakrish Nair,\* David A. Sack,\*  
Marcelino Lucas,†  
Jacqueline L. Deen,‡  
Julia Ampuero,§¶  
Claire-Lise Chagnat,#  
and The Mozambique Cholera  
Vaccine Demonstration Project  
Coordination Group<sup>1</sup>**

\*Centre for Health and Population Research, Dhaka, Bangladesh; †Ministério da Saude, Maputo, Mozambique; ‡International Vaccine Institute, Seoul, Korea; §Médecins Sans Frontières, Geneva, Switzerland; ¶Epicentre, Paris, France; and #World Health Organization, Geneva, Switzerland

### References

1. Waldor MK, Mekalanos JJ. Lysogenic conversion by a filamentous phage encoding cholera toxin. *Science*. 1996;272:1910–4.
2. Kimsey HH, Nair GB, Ghosh A, Waldor MK. Diverse CTXÖs and evolution of new pathogenic *Vibrio cholerae*. *Lancet*. 1998;352:457–8.
3. Popovic T, Fields PI, Olsvik O. Detection of cholera toxin genes. In: Wachsmuth IK, Blake PA, Olsvik O, editors. *Vibrio cholerae* and cholera: molecular to global perspectives. Washington: American Society for Microbiology; 1994. p. 41–52.
4. Davis BM, Waldor MK. Filamentous phages linked to virulence of *Vibrio cholerae*. *Curr Opin Microbiol*. 2003;6:35–42.
5. Nair GB, Faruque SM, Bhuiyan NA, Kamruzzaman M, Siddique AK, Sack DA. New variants of *Vibrio cholerae* O1 biotype El Tor with attributes of the classical biotype from hospitalized patients with acute diarrhea in Bangladesh. *J Clin Microbiol*. 2002;40:3296–9.

Address for correspondence: David Sack, Executive Director, ICDDR,B, Centre for Health and Population Research, P.O. Box 128, Mohakhali, Dhaka 1000, Bangladesh; fax: 880-2-882-3116; email: dsack@icddr.org

<sup>1</sup>The group includes participants from the: Ministério da Saude, Maputo, Mozambique (Avertino Barreto, Juvenaldo Amos, Catarina Mondlane, and Raul Vaz); International Vaccine Institute (John D. Clemens, Lorenz von Seidlein, Xuan-Yi Wang, Mohammad Ali, and Mahesh K Puri); Médecins Sans Frontières, Geneva, Switzerland (Claude Mahoudeau, Bruno Lab, Gérard Bedock, Valerie Perroud, and Margaret McChesney); Epicentre, Paris, France (Philippe J. Guerin, Dominique Legros, and Philippe Cavailler); World Health Organization, Geneva, Switzerland (Marie-Paule Kieny and Duncan Steele); and World Health Organization, Maputo, Mozambique (Bocar Touré and Pierre Kahozi).

Use of trade names is for identification only and does not imply endorsement by the Public Health Service or by the U.S. Department of Health and Human Services.

### Correction, vol. 10, no. 10

In "Scrub Typhus in the Republic of Palau, Micronesia," by A. Mark Durand et al. (p. 1840), Table 2 was incorrect. The correct version appears below and online at <http://www.cdc.gov/ncidod/eid/vol10no10/04-0288.htm#table2>. We regret any confusion this error may have caused.

Table 2. *Orientia tsutsugamushi* IgG and IgM antibody titers for six southwest islanders with prolonged fever and abdominal distress<sup>a</sup>

Patient no.	Antibody type	Acute-phase titer	Convalescent-phase titer
1	IgG	1:2,048	NA
	IgM	1:16,384	NA
2	IgG	NA	1:32,768
	IgM	NA	1:2,048
3	IgG	1:262,144	1:262,144
	IgM	1:4,096	1:1,024
4	IgG	1:65,536	1:65,536
	IgM	1:1,024	1:2,048
5	IgG	1:8,000	1:64,000
	IgM	NA	NA
6	IgG	1:4,000	1:64,000
	IgM	NA	NA

<sup>a</sup>Ig, immunoglobulin; NA, result not available.

### Instructions for Emerging Infectious Diseases Authors

#### Letters

Letters commenting on recent articles as well as letters reporting cases, outbreaks, or original research are welcome. Letters commenting on articles should contain no more than 300 words and 5 references; they are more likely to be published if submitted within 4 weeks of the original article's publication. Letters reporting cases, outbreaks, or original research should contain no more than 800 words and 10 references. They may have one Figure or Table and should not be divided into sections. All letters should contain material not previously published and include a word count.